This database provides a catalog of the therapeutics currently or previously tested as treatment for Alzheimer's disease and related disorders, focusing on those that have progressed to Phase 2 or beyond in U.S. clinical trials. We strive to keep this database up-to-date and welcome you to contact us at firstname.lastname@example.org.
AD Target / Therapy Types
The two tables below organize the therapeutics within this database by therapy type and proposed target type. The number of therapeutics within each category is indicated according to the highest phase each therapeutic has achieved in U.S. clinical trials. For example, if a given therapeutic is in both Phase 2 and Phase 3 trials, it is included in the Phase 3 total.
|Target Types||Timeline||Phase 1||Phase 1/2||Phase 2||Phase 2/3||Phase 3||Phase 4||Approved||Rejected||Inactive||Discontinued||Not Regulated||Total|
|Cholinergic System||View Timeline||1||0||1||0||2||0||4||0||6||18||0||32|
|Other Neurotransmitters||View Timeline||2||0||14||1||9||3||1||1||2||21||0||54|
|Therapy Types||Timeline||Phase 1||Phase 1/2||Phase 2||Phase 2/3||Phase 3||Phase 4||Approved||Rejected||Inactive||Discontinued||Not Regulated||Total|
|Immunotherapy (active)||View Timeline||3||0||6||0||0||0||0||0||1||4||0||14|
|Immunotherapy (passive)||View Timeline||14||2||6||1||3||0||2||0||2||14||0||44|
|Small Molecule||View Timeline||16||2||52||6||21||6||6||1||22||76||0||208|
|Supplement, Dietary||View Timeline||0||2||5||2||1||3||0||0||1||2||4||20|
- Legacy of A4 Secondary Prevention Study Goes Beyond Negative Result
- Does Flashing Light Really Lower Cortical Amyloid?
- Decision Date on Leqembi Traditional Approval Set for July
- Gene Editing for Huntington’s Disease Shows Promise in Pigs
- Suzanne Hendrix on Constructing Composites for Trials in Early Alzheimer’s
- Computational Modeling—Will it Rescue AD Clinical Trials?
- Resolving Controversies on the Path to AD Therapeutics
- Treating Before Symptoms—ADCS Invites Ideas for Clinical Trials in Very Early AD
ADataViewer is an interactive platform that facilitates the exploration of 20 cohort datasets with respect to longitudinal follow-up, demographics, ethnoracial diversity, measured modalities, and statistical properties of individual variables.
ADDF ACCESS is a program to provide scientists in academia and small biotechnology companies with access to a virtual network of drug discovery experts and contract research organizations (CROs) that have experience developing therapies for neurodegenerative diseases.